Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

This trial is comparing two second-line chemotherapy combinations for people with advanced colorectal cancer that has stopped responding to initial treatment. One combination uses bevacizumab (a drug that blocks tumor blood vessel growth) and the other uses cetuximab (a drug that blocks a growth signal in cancer cells), both paired with standard chemotherapy. **You may be eligible if...** - You are 18–75 years old with metastatic colorectal cancer confirmed by tissue testing - Your cancer progressed on or after one prior line of treatment - You are reasonably functional (ECOG 0–1) and expected to survive at least 3 months - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have had more than one prior line of systemic treatment for advanced disease - You have serious heart, kidney, or liver problems - You are pregnant or breastfeeding - Your cancer has spread to the brain Talk to your doctor to see if this trial is right for you.